Company: LCTX
Filing Date: 2025-06-23
Form Type: 8-K
Source: 0000950170-25-088738
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-06-23
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On June 23, 2025, Lineage Cell Therapeutics, Inc. (“we,” “us,” “our,” the “ Company,” or “ Lineage”) issued a press release announcing 36-month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials. gov Identifier: NCT02286089) of RG6501 (OpRegen®) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), which were presented at Clinical Trials at the Summit (CTS) 2025 by Christopher D. Riemann, M. D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine, on behalf of Roche and Genentech, a member of the Roche Group. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01 and in Exhibit 99.1 to this report is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.